Compare HCWB & MEHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HCWB | MEHA |
|---|---|---|
| Founded | 2018 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7M | 3.4M |
| IPO Year | 2021 | N/A |
| Metric | HCWB | MEHA |
|---|---|---|
| Price | $0.72 | $0.15 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $35.00 | N/A |
| AVG Volume (30 Days) | ★ 20.4M | 9.3M |
| Earning Date | 03-27-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,099,750.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.22 | $0.13 |
| 52 Week High | $17.80 | $0.74 |
| Indicator | HCWB | MEHA |
|---|---|---|
| Relative Strength Index (RSI) | 47.75 | 33.83 |
| Support Level | $0.48 | N/A |
| Resistance Level | $0.78 | $0.32 |
| Average True Range (ATR) | 0.15 | 0.03 |
| MACD | 0.05 | -0.00 |
| Stochastic Oscillator | 34.84 | 12.52 |
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
Functional Brands Inc operates in the nutraceutical supplement industry. It is a manufacturer and distributor of supplements in categories such as pain, energy, prenatal, general health, bone and joint, gastro, immunity, cardiac, detox, brain and memory, sleep, prenatal and urinary. It is focus on end-consumers through different channels that include pharmacies, wholesalers, international distributors and direct-to-consumers sales. The Company has two reportable segments: 1) Kirkman, which sells a range of nutraceuticals, supplements and related products direct to consumers; 2) HT Naturals, which sells a range of hemp products; and 3) Corporate, which generates no revenue. Key revenue is generated from Kirkman.